22 July 2019

The new prospectus regime – Key changes for Luxembourg

The underlying legislative framework has been entirely changed, but the principles remain substantially the same. The new prospectus regime is fully effective as of 21 July 2019.
The Prospectus Regulation replaced the Prospectus Directive and its implementing laws. The new prospectus regime will change in particular the prospectus summary and the disclosure of the risk factors.

Issuers of equity and non-equity securities on a continuous basis may use the Universal Registration Document to have a faster access to the capital markets. Qualifying issuers, mainly SMEs, will be allowed to prepare a simplified EU Growth Prospectus. The lighter wholesale disclosure regime applies also to non-equity securities, regardless of their denomination, which are admitted to trading on a segment of a regulated market accessible only to qualified investors. The exemption regime has been slightly changed, now allowing the offering of securities of up to EUR 8 million without a prospectus in Luxembourg (crowdfunding exemption).

This GSK Update highlights further details and discusses what to expect.

Print


Press contact
Beate Dünschede
+352 271802-29
beate.duenschede@gsk-lux.com

Back

GSK Updates
  • 17.08.2022

    GSK Update: CAA Circular 22/15: What is new for the governance of insurance and reinsurance companies

    Read more
  • 10.02.2022

    GSK Update: Update of the Luxembourg Securitisation Law: Increased Flexibility and Legal Certainty

    Read more
  • 27.01.2022

    GSK Update: CSSF Guidance on Virtual Assets: New FAQ for UCI and credit institutions

    Read more
Contact person

Andreas Heinzmann, LL.M.

Partner

+352 271802-30

andreas.heinzmann@gsk-lux.com

Dr. Philipp Mössner, LL.M.

Partner

+352 271802-40

philipp.moessner@gsk-lux.com

Anna Lindner

Senior Associate

+352 271802-43

anna.lindner@gsk-lux.com

Valerio Scollo, LL.M.

Local Partner

+352 271802-32

valerio.scollo@gsk-lux.com

© GSK Stockmann 2022